Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX E 2 75 5 SULFITE FREE W ELECT IN DEXTROSE 5 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 4 25 IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINIMIX E 2 75 5 SULFITE FREE W ELECT IN DEXTROSE 5 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 4 25 IN DEXTROSE 5 IN PLASTIC CONTAINER.
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER vs TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CLINIMIX E 2.75/5 is a combination of amino acids, electrolytes, and dextrose used for parenteral nutrition. The amino acids provide substrates for protein synthesis, dextrose supplies caloric energy, and electrolytes maintain acid-base and fluid balance. Calcium is included for bone health and neuromuscular function.
Travasol 4.25% in dextrose 5% is a parenteral nutrition solution providing amino acids and carbohydrates. Amino acids serve as substrates for protein synthesis and other metabolic processes, while dextrose provides a source of glucose for energy. The combination supports tissue repair, growth, and maintenance.
Intravenous administration. The dose is individualized based on patient's metabolic requirements, clinical condition, and tolerance. Typical adult dose: 1 to 2 L per day of CLINIMIX E 2.75/5 with electrolytes in 5% dextrose with calcium, infused at a rate not exceeding 4 mg/kg/min of dextrose (or as tolerated).
Intravenous infusion: 500-2000 mL per day as a source of amino acids and calories, adjusted based on metabolic needs and clinical response. Typical adult dose is 1.5-2.0 g/kg/day of amino acids (equivalent to 35-47 mL/kg/day of TRAVASOL 4.25% IN DEXTROSE 5%) administered via central or peripheral line.
None Documented
None Documented
Not applicable as a single entity; components have independent half-lives. Amino acids have plasma half-lives of minutes to hours depending on individual amino acid and metabolic state. Dextrose has an elimination half-life of 1.5-2.5 hours in normal glucose tolerance. Electrolytes are not described by half-life due to homeostatic regulation.
Not applicable as a combined product; amino acids have half-lives of minutes to hours depending on individual amino acid, and dextrose has a half-life of ~15-20 minutes under normal glucose homeostasis.
CLINIMIX E 2.75/5 is a parenteral nutrition solution; components are eliminated via normal metabolic pathways. Amino acids undergo deamination and oxidation, with nitrogen excreted renally as urea (80-90%). Glucose is metabolized to CO2 and water, excreted via lungs and kidneys. Electrolytes are excreted renally in proportion to intake and homeostatic regulation.
Travasol 4.25% in dextrose 5% is a parenteral nutrition solution; the amino acids are metabolized and the nitrogen is excreted primarily in urine as urea (≥90%). Dextrose is metabolized to CO2 and water, with minimal biliary or fecal excretion.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution